Syndrome de Prader-Willi

Overview

Le syndrome de Prader-Willi (PWS) est une maladie génétique rare et à vie qui affecte environ 1 personne sur 10 000 à 30 000. Cela survient lorsqu’un groupe de gènes normalement actifs sur la copie paternelle du chromosome 15q11–q13 est manquant ou éteint; les gènes maternels correspondants sont généralement présents mais naturellement silenciés par l’empreinte génomique, un système épigénétique qui marque les gènes selon le parent dont ils proviennent. [GeneReviews: Prader-Willi Syndrome] Le PWS commence généralement par une hypotonie et des difficultés d’alimentation chez le nourrisson, puis évolue vers des différences développementales et d’apprentissage, des déficits hormonaux, des défis comportementaux, des troubles du sommeil et, dans l’enfance, une hyperphagie sévère — faim persistante avec peu de sensation de satiété — qui peut entraîner une obésité dangereuse sans une surveillance alimentaire stricte. [GeneReviews: Prader-Willi Syndrome]

PWS has no cure. Current care is lifelong and multidisciplinary: controlled access to food, a calorie-managed diet, physical activity, growth-hormone treatment when appropriate, hormone replacement, developmental therapies, behavioral and mental-health support, and monitoring for sleep, orthopedic, and metabolic complications. GeneReviews: Prader-Willi Syndrome These measures can substantially improve health and independence, but they do not restore the missing paternal gene program. NIH RePORTER: Reactivating maternal PWS genes

Scope of Recent Research (2020–present)

Recent PWS research has become more biologically ambitious: alongside drugs intended to reduce hunger or improve behavior, investigators are trying to reactivate the intact but silent maternal chromosome 15 gene cluster. The dominant curative question is whether targeted epigenome editing—altering gene-control marks without cutting DNA—can safely restore enough paternal-gene-like activity in the relevant brain cells to change disease biology. The direct cure-oriented work remains preclinical, primarily in patient-derived cells, hypothalamic organoids, and mouse models; human trials currently focus on symptoms rather than genetic correction. Activation of the PWS locus by CRISPR epigenome editing Rescue of imprinted genes by epigenome editing

Major Breakthroughs and Emerging Therapies

The most important potential curative strategy is maternal-allele reactivation. Unlike many deletion disorders, PWS often leaves a structurally intact maternal copy of the relevant chromosome 15 genes. The challenge is that this copy is epigenetically silenced. Researchers are therefore using CRISPR-derived “dead” Cas9, or dCas9, which can be guided to DNA but does not cut it, to bring activating proteins to the PWS imprinting-control region near SNRPN. [Activation of the PWS locus by CRISPR epigenome editing] This approach could, in principle, restore several PWS-associated genes together, including the important non-coding RNA cluster SNORD116, rather than requiring separate replacement of each gene. GeneReviews: Prader-Willi Syndrome

A major advance came from CRISPR epigenome-editing experiments in human induced pluripotent stem cells (iPSCs), cells reprogrammed from patients that can be converted into neurons. Researchers used dCas9 linked either to a transcriptional activator or to TET1, an enzyme that removes DNA methylation marks. Both strategies reactivated maternal SNRPN and downstream PWS transcripts, while transient TET1-based editing produced persistent activation that remained detectable after the cells became neurons. [Activation of the PWS locus by CRISPR epigenome editing] This is an important proof of concept because it suggests that a limited treatment exposure might create a durable change in the disease-relevant gene-control state.

A 2025 study extended this work into patient-derived hypothalamic organoids—three-dimensional cell models intended to better approximate the brain region central to hunger, endocrine regulation, and many PWS features. Targeted demethylation of the PWS imprinting-control region reactivated maternally silenced PWS genes, and the altered expression persisted during organoid differentiation while partially reversing PWS-associated molecular patterns. [Rescue of imprinted genes by epigenome editing] These findings are promising, but they remain laboratory results rather than evidence that an editor can safely reach and benefit a person’s hypothalamus.

A related delivery effort is testing non-viral delivery of dCas9 epigenome editors as ribonucleoprotein complexes. Yale investigators supported by the Foundation for Prader-Willi Research (FPWR) are evaluating systems that couple dCas9 to TET1 or JMJD2a, another epigenetic enzyme, to reactivate maternal PWS genes in mouse models and patient-derived neurons. [FPWR: Non-viral CRISPR epigenome-editing delivery] The goal is to avoid permanent insertion of a viral gene-therapy cassette while improving delivery to the central nervous system.

Broader epigenetic drugs, including inhibitors of enzymes that maintain gene silencing, have also reactivated maternal PWS genes in experimental systems. However, because those enzymes act throughout the genome, they may change many unintended genes; this has shifted emphasis toward locus-specific CRISPR epigenome editing. [Rescue of imprinted genes by epigenome editing] A central safety issue is preserving normal neuronal expression of UBE3A: excessive disruption of UBE3A imprinting could theoretically create Angelman-syndrome-like consequences. Activation of the PWS locus by CRISPR epigenome editing

Clinical Trials and Experimental Approaches

The most consequential clinical advance since 2020 has been symptomatic rather than curative. On March 26, 2025, the U.S. Food and Drug Administration approved diazoxide choline extended-release tablets, sold as Vykat XR, for hyperphagia in people with PWS aged four years and older. [FDA orphan-drug approval record for Vykat XR] The drug does not correct the chromosome 15 imprinting defect, but it provides the first FDA-approved medicine specifically indicated for the relentless hunger that drives many PWS complications. [GeneReviews: Prader-Willi Syndrome]

Several ongoing or recently reported trials target appetite circuitry. Rhythm Pharmaceuticals’ Phase 1/2 study of the weekly melanocortin-4 receptor agonist RM-718 includes a PWS cohort, with safety, tolerability, and pharmacokinetics as early objectives. [ClinicalTrials.gov: RM-718 study] The company also reported six-month Phase 2 data for setmelanotide in 17 people with PWS, describing reductions in body-mass measures, fat mass, hyperphagia, and anxiety; these sponsor-reported findings require confirmation in larger controlled studies. [Rhythm Pharmaceuticals second-quarter 2026 update]

Recent setbacks illustrate the difficulty of translating symptom therapies. Acadia reported on September 24, 2025, that its Phase 3 COMPASS PWS trial of intranasal carbetocin did not significantly improve primary or secondary outcomes over placebo and that it would not continue the program. [Acadia COMPASS PWS community letter] Aardvark’s Phase 3 HERO study of ARD-101, a gut-restricted bitter-taste-receptor agonist intended to reduce hunger, was terminated early after 67 of 90 planned participants were randomized; on October 23, 2026, the company characterized the available efficacy results as exploratory, although the FDA had lifted the prior clinical hold one day earlier. [Aardvark: exploratory HERO and extension data]

Methodologies and Scientific Approaches

Cure-oriented researchers combine molecular and functional models. Patient-derived iPSCs permit testing in cells with paternal deletions, maternal uniparental disomy, or imprinting defects; these cells can then be differentiated into neurons or hypothalamic organoids. Researchers measure whether editing restores SNRPN, SNORD116, and related transcripts; whether methylation and chromatin accessibility normalize; and whether disease-associated gene-expression patterns improve. [Activation of the PWS locus by CRISPR epigenome editing] [Rescue of imprinted genes by epigenome editing]

Delivery is now the key translational problem. Programs are comparing viral vectors such as the virus adéno-associé (AAV) with non-viral dCas9-ribonucleoprotein platforms, as well as intravenous and intrathecal administration, while assessing biodistribution, off-target epigenetic effects, durability, and effects on UBE3A. [FPWR: Non-viral CRISPR epigenome-editing delivery] Animal studies are especially important for determining whether treatment must begin before, during, or after critical stages of hypothalamic development. [NIH RePORTER: Reactivating maternal PWS genes]

Leading Institutions and Funding

Duke University, the Broad Institute of MIT and Harvard, and collaborating investigators produced the recent human-iPSC CRISPR work identifying regulatory sites that can activate maternal PWS genes. [Activation of the PWS locus by CRISPR epigenome editing] Keio University researchers led the 2025 organoid study showing PWS-locus reactivation in patient-derived cellular models. [Rescue of imprinted genes by epigenome editing] Yale University School of Medicine is advancing the non-viral delivery strategy, while companies including Soleno, Rhythm, and Aardvark are running or planning symptom-directed drug studies. [FPWR: Non-viral CRISPR epigenome-editing delivery] [ClinicalTrials.gov: RM-718 study]

Patient organizations are unusually important funders in this rare-disease field. FPWR awarded $162,000 to a Duke project developing sustained maternal-gene reactivation and another $162,000 to Yale’s non-viral epigenome-editing delivery project. [FPWR: Sustained maternal PWS-gene reactivation] [FPWR: Non-viral CRISPR epigenome-editing delivery] FPWR’s current grant mechanism permits up to $150,000 in direct costs over an initial 18-month project, and NIH-supported projects are pursuing in-vivo testing of PWS epigenome editors. [FPWR research grant program] [NIH RePORTER: Reactivating maternal PWS genes]

Strengths, Limitations, and Challenges

The field’s greatest strength is that PWS offers a biologically plausible restoration strategy: in many cases, the needed maternal genes are present but silent rather than destroyed. Targeted epigenome editing could therefore restore a coordinated gene network from its natural genomic location, potentially avoiding the problem of selecting and dosing many separate replacement genes. [Activation of the PWS locus by CRISPR epigenome editing] The use of patient-specific neurons and hypothalamic organoids is also improving the relevance of preclinical testing. [Rescue of imprinted genes by epigenome editing]

The limitations are substantial. Researchers must achieve widespread, durable, and cell-type-appropriate delivery to the brain; reactivate enough PWS genes without altering other loci; avoid harmful effects on neuronal UBE3A expression; and establish benefit across the genetically diverse forms of PWS. [Rescue of imprinted genes by epigenome editing] It is also unknown whether reactivating genes after birth—or later in childhood or adulthood—can reverse developmental changes already established in the brain; this is an inference from the field’s current emphasis on treatment timing in animal models, not yet a resolved clinical question. [FPWR: Non-viral CRISPR epigenome-editing delivery]

Perspectives et orientations futures

À la date du 27 octobre 2026, le syndrome de Prader-Willi (PWS) n’est pas proche d’un remède clinique démontré, mais il est plus proche d’une stratégie de cure rationnelle qu’au début de la décennie. Les étapes à surveiller sont le rétablissement reproductible de caractéristiques pertinentes du PWS dans des modèles animaux ; une délivrance sûre et adaptée au cerveau d’éditeurs de l’épigénome transitoires ou auto-limitants ; une restauration durable du bon ensemble de gènes maternels sans perturber UBE3A ; et une première soumission réglementaire pour une étude d’édition génique ou épigénomique chez l’humain. D’ici là, des traitements de l’appétit approuvés et expérimentaux peuvent réduire le fardeau, mais seule la réactivation du locus maternel aborde directement le mécanisme génétique de base. Activation of the PWS locus by CRISPR epigenome editing Rescue of imprinted genes by epigenome editing

Références

• Prader-Willi Syndrome — Driscoll, Miller et Cassidy; GeneReviews, 2026.
• Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing — Rohm et al.; Cell Genomics, 2025.
• Restauration des gènes imprintés par édition de l’épigénome dans des modèles cellulaires humains du syndrome de Prader-Willi — Nemoto et al.; Nature Communications, 2025.
• NIH RePORTER: Reactivating maternal PWS genes — National Institutes of Health, 2026.
• FDA orphan-drug approval record for Vykat XR — U.S. Food and Drug Administration, 2025.
• ClinicalTrials.gov: RM-718 study — Bibliothèque nationale de médecine, 2026.
• Rhythm Pharmaceuticals second-quarter 2026 update — Rhythm Pharmaceuticals, 2026.
• Acadia COMPASS PWS community letter — Acadia Pharmaceuticals, 2025.
• Aardvark: exploratory HERO and extension data — Aardvark Therapeutics, 2026.
• FPWR: Sustained maternal PWS-gene reactivation — Foundation for Prader-Willi Research, 2025.
• FPWR: Non-viral CRISPR epigenome-editing delivery — Fondation pour la Recherche sur le Prader-Willi, 2024.
• FPWR research grant program — Fondation pour la Recherche sur le Prader-Willi, 2026.